Literature DB >> 25030841

A new era in medical therapy for retinal degenerative disease?

Alessandro Iannaccone1, Marco A Zarbin2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25030841     DOI: 10.1016/S0140-6736(14)60956-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Reliability of kinetic visual field testing in children with mutation-proven retinal dystrophies: Implications for therapeutic clinical trials.

Authors:  Vaidehi S Dedania; Jerry Y Liu; Dana Schlegel; Chris A Andrews; Kari Branham; Naheed W Khan; David C Musch; John R Heckenlively; K Thiran Jayasundera
Journal:  Ophthalmic Genet       Date:  2017-07-13       Impact factor: 1.803

Review 2.  Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium.

Authors:  Debra A Thompson; Robin R Ali; Eyal Banin; Kari E Branham; John G Flannery; David M Gamm; William W Hauswirth; John R Heckenlively; Alessandro Iannaccone; K Thiran Jayasundera; Naheed W Khan; Robert S Molday; Mark E Pennesi; Thomas A Reh; Richard G Weleber; David N Zacks
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-02-09       Impact factor: 4.799

3.  Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT).

Authors:  Hendrik P N Scholl; Anthony T Moore; Robert K Koenekoop; Yuquan Wen; Gerald A Fishman; L Ingeborgh van den Born; Ava Bittner; Kristen Bowles; Emily C Fletcher; Frederick T Collison; Gislin Dagnelie; Simona Degli Eposti; Michel Michaelides; David A Saperstein; Ronald A Schuchard; Claire Barnes; Wadih Zein; Ditta Zobor; David G Birch; Janine D Mendola; Eberhart Zrenner
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.